Friday, September 23, 2016 10:24:01 AM
Maverick, just a brief reply to your commentary a short time ago, hard to keep up these days. Pfizer, as evidenced by their Medivation move, like all BP need to be in the oncology space, given their size and the size of the oncology space. It gets harder to grow such large entities when product lines have such limited patent lives. Pfizer is getting good mileage out of their Wyeth acquisition with growth from Prevnar and their bank account expanded from when they sold the infant formula business to Nestle. Pfizer is not known for R&D productivity but for their financial mgmt. and their marketing machine. So, I think you can suffice it to say all BP have a stake in the oncology game.
And, it appears NWBO Has built something of significant potential. I think NWBO is determined to get through with full control of their products until they make a deal with strength. How they are going to get there if good news is not out very soon about their P3 L trial I am not sure. The best way appears to publish the investigation results and keep NW engaged, which at these prices seems doable. I suspect the investigation has gotten deep and needs to stay focused and has probably named an endpoint but I am hopeful they do not try to save the investment world, just do what they can while saving NWBO. One defense they have going for them is Cognate since no one would try to muscle move on NWBO without the mfg included and NWBO has shielded that.
So, I like the AZ possibility, as they are a rather desperate company for growth, more than most BP currently are, though the competition for good growth assets is high. I also like Roche. The more the merrier since NWBO Has something potentially disruptive to this market if 1 entity was able to lock it up once proven. Once P3 is announced the negotiating table gets set if NWBO wants a real partner, which may make sense here. We will see soon.
RK and Flipper and others, thx so much for the clinical study and scientific approach evaluative work, so valuable to all investors here.
I strongly urge all investors here, particularly any new ones, to pay close attention to the qualified posters here and not the AF's and not the other baseless attacking posters here.
Good luck to all here.
And, it appears NWBO Has built something of significant potential. I think NWBO is determined to get through with full control of their products until they make a deal with strength. How they are going to get there if good news is not out very soon about their P3 L trial I am not sure. The best way appears to publish the investigation results and keep NW engaged, which at these prices seems doable. I suspect the investigation has gotten deep and needs to stay focused and has probably named an endpoint but I am hopeful they do not try to save the investment world, just do what they can while saving NWBO. One defense they have going for them is Cognate since no one would try to muscle move on NWBO without the mfg included and NWBO has shielded that.
So, I like the AZ possibility, as they are a rather desperate company for growth, more than most BP currently are, though the competition for good growth assets is high. I also like Roche. The more the merrier since NWBO Has something potentially disruptive to this market if 1 entity was able to lock it up once proven. Once P3 is announced the negotiating table gets set if NWBO wants a real partner, which may make sense here. We will see soon.
RK and Flipper and others, thx so much for the clinical study and scientific approach evaluative work, so valuable to all investors here.
I strongly urge all investors here, particularly any new ones, to pay close attention to the qualified posters here and not the AF's and not the other baseless attacking posters here.
Good luck to all here.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
